Langerhans cells (LCs), a sub-population of dendritic cells (DCs) in the skin, participate in the regulation of immunity and peripheral tolerance. The adaptor molecule p14 is part of the late endosomal/lysosomal adaptor and mitogen-activated protein kinase and mammalian target of rapamycin (mTOR) activator/regulator (LAMTOR) complex, which mediates the activation of lysosome-associated extracellular signaling-regulated kinase (ERK) and the mTOR cascade. In previous work, we demonstrated that CD11c-specific deficiency of p14 disrupts LC homeostasis by affecting the LAMTOR-mediated ERK and mTOR signaling. In this study, we extended our analysis on p14 deficiency specifically in LCs. Langerin-specific ablation of p14 caused a complete loss of LCs, accompanied by an increased maturational phenotype of LCs. The absence of LCs in p14-deficient mice reduced contact hypersensitivity (CHS) responses to the contact sensitizer trinitrochlorobenzene. Analysis using bone marrow-derived DCs (BMDCs) revealed that p14 deficiency in DCs/LCs interfered with the LC-relevant transforming growth factor b1 (TGFb1) pathway, by lowering TGFb receptor II expression on BMDCs and LCs, as well as surface binding of TGFb1 on BMDCs. We conclude that p14 deficiency affects TGFb1 sensitivity of LCs, which is mandatory for their homeostasis and subsequently for their immunological function during CHS.
INTRODUCTION
Langerhans cells (LCs) are resident dendritic cells (DCs) in the epidermis of the skin and have been shown to participate in the induction of immunity, as well as peripheral tolerance (Merad et al., 2008; Romani et al., 2010) . To do so, they need to ingest, process, and finally present foreign antigen, as well as self-antigen, bound to major histocompatibility complex (MHC) molecules to T cells. A prerequisite for antigen presentation is an efficient, intracellular endosomal sorting machinery, which is controlled by several proteins including adaptor and scaffold molecules.
Among others, the adaptor molecule p14, also termed late endosomal/lysosomal adaptor and mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR) activator/regulator complex 2 (LAMTOR2), regulates endosomal rearrangement, as well as other fundamental cellular processes such as growth factor signaling and proliferation in nonimmune but also immune cells (Teis et al., 2006; Taub et al., 2012) . More importantly, deficiency of p14 is the molecular cause for the development of a hitherto unknown primary human immunodeficiency syndrome, which displays hallmarks reminiscent of diseases such as Griscelli and Hermansky-Pudlak syndrome (Klein et al., 1994; Dell'Angelica et al., 1999; Ménasché et al., 2000; Jung et al., 2006) . Recent work demonstrated that p14 exerts its function by participating in the formation of the LAMTOR complex, which consists of five adaptor and scaffolding molecules: p18 (LAMTOR1), p14 (LAMTOR2), MP1 (LAMTOR3), HPXIP (LAMPTOR4), and C7orf59 (LAMTOR5). The LAMTOR complex represents the signaling platform important for the correct spatiotemporal activation of the extracellular signal-regulated kinase (ERK) MAPK, as well as the mTORC1 pathways at the stage of multivesicular bodies and lysosomes (Wunderlich et al., 2001; Teis et al., 2002; Nada et al., 2009; Sancak et al., 2010; Magee and Cygler, 2011; Bar-Peled et al., 2012) .
In previous work (Sparber et al., 2014) , we identified p14 as an important regulator for LC homeostasis, as its CD11c-specific deletion led to a virtually complete loss of LCs in p14-deficient mice. This was mainly owing to increased apoptosis and cell cycle arrest of LCs. At the molecular level, we determined that the p14-mediated disruption of the LAMTOR complex and the subsequently impaired ERK and mTOR signaling caused the loss of LCs. However, because of the pivotal function of p14 in regulating growth factor signaling, we sought to extend our previous findings and further investigated p14 deficiency in LCs with special focus on the LC-relevant transforming growth factor b1 (TGFb1) signaling pathway.
RESULTS
Langerin-specific deletion of p14 leads to a loss of Langerin Recently, we demonstrated that genetic deletion of the adaptor molecule p14 under the control of the cd11c promoter (CD11c-p14 del mice) resulted in a complete loss of epidermal LCs. To further investigate p14 deficiency in LCs, we now specifically deleted p14 under the control of the langerin/CD207 promoter by using Langerin-Cre mice (Zahner et al., 2011) and analyzed the DC subsets in the skin-draining LNs of adult Langerin-p14 del and littermate control mice. LNs of adult Langerin-p14 del mice were of comparable size to those of wild-type controls, and we could not detect any significant differences in the percentages of total LN- (Figure 1a and d) . Hence, our data demonstrate that langerinspecific ablation of p14 resulted in a specific loss of Langerin þ migratory DCs in the skin-draining LNs of Langerin-p14 del mice, which corroborates our previous observation concerning the loss of Langerin þ migratory DCs after CD11c-specific deletion of p14 (Sparber et al., 2014) .
LCs are gradually lost in the skin of newborn Langerin-p14 del mice Similar to the analysis of CD11c-p14 del mice (Sparber et al., 2014) , we analyzed the skin of newborn Langerin-p14 del and control mice on defined time points after birth. In concordance with our previous data, we observed a gradual loss of epidermal LCs in Langerin-p14 del mice. Intriguingly, we could not detect any significant difference in the percentages of LCs between Langerin-p14 del and control mice during the first week after birth, suggesting normal population of the epidermis by LCs. However, p14-deficient LCs gradually declined approximately at 3 weeks of age (Figure 2a, b , and e). The delayed loss of LCs in the Langerin-p14 del mice when compared with CD11c-p14 del mice (Sparber et al., 2014) Figure S1 online) . Reminiscent of CD11c-p14 del animals, the loss of LCs in Langerin-p14 del mice was accompanied by a more mature phenotype of the cells, as indicated by elevated expression of CD86 by Langerin þ CD103 À LCs from whole skin cell suspensions (Figure 2c ). At the same time, Langerin expression decreased on LCs (Figure 2c ). In addition, in pure epidermal cell suspensions, we could confirm this enhanced maturation of p14-deficient LCs, as these cells showed increased MFI of CD86 and MHC-class II. As mentioned above, we noticed MHC-class II þ Langerin low cells besides the MHC-class II þ Langerin þ LC population (Figure 2f ). Annexin-V revealed an increased staining, indicating that Langerin low cells could represent apoptotic LCs that had partially lost Langerin and MHC-class II expression (Supplementary Figure S2 online) . In contrast to LCs, we could not detect a reduction of Langerin þ dermal DCs in Langerin-p14 del mice (Figure 2d ). This differs from our observation in the skin of CD11c-p14 del mice, which displayed a significantly reduced frequency of Langerin þ dermal DCs (Sparber et al., 2014) .
In summary, our data demonstrate that langerin-specific deletion of p14 leads to a gradual loss of LCs in situ starting 3 weeks after birth, which is accompanied by an increased phenotypic maturation status of the LCs and decreased expression of Langerin.
Absence of LCs in Langerin-p14 del mice impairs contact hypersensitivity (CHS) response
As the role of LCs in CHS remains controversial (Noordegraaf et al., 2010; Romani et al., 2010) , we assessed the immunological consequence of the loss of LCs in Langerinp14 del mice in the CHS response to the contact sensitizer trinitrochlorobenzene (Picrylchlorid, TNCB). Langerin-p14 del and control mice were sensitized with 1% (high dose) or 0.5% (low dose) TNCB on abdominal skin and 5 days later they were challenged with either 0.5% (high dose) or 0.25% (low dose) on the ear skin, respectively (Figure 3a) . With both doses of TNCB, Langerin-p14 del mice displayed a significantly reduced ear swelling reaction 24 hours after TNCB challenge as compared with controls ( Figure 3b ). Hence, our data demonstrate that the loss of LCs by Langerin-specific ablation of p14 reduces TNCB-mediated CHS responses, similar to animals with a selective LC deficiency due to disrupted TGFb signaling (Zahner et al., 2011) .
CD11c-specific deletion of p14 impairs TGFb1-mediated generation of LC-like bone marrow-derived DCs (LCL-BMDCs) and facilitates their enhanced maturation Analysis of the molecular mechanism of p14 deficiency in CD11c-p14 del BMDCs established that deletion of p14 leads to a partial disruption of the ERK and mTORC1 signaling pathway (Sparber et al., 2014) . The latter pathway has already been shown to affect LC homeostasis, as CD11c-specific F Sparber et al.
The Endosomal Adaptor p14 Affects TGFb1 Pathway in Langerhans Cells deletion of the mTORC1-related regulatory-associated protein of mTOR (RAPTOR) molecule led to a loss of LCs in situ (Kellersch and Brocker, 2013) . However, we observed an increased maturation of p14-deficient LCs, which was not apparent in RAPTOR-deficient mice (Kellersch and Brocker, 2013; Sparber et al., 2014) . As TGFb1 is essential for the development and homeostasis of LCs, as well as the maintenance of the immature status of LCs in the epidermis of LCs in the skin (Borkowski et al., 1997; Kaplan et al., 2007; Kel et al., 2010) , we hypothesized that p14 deficiency might also affect TGFb1 signaling in LCs. It is, however, very difficult to isolate sufficient amounts of highly purified LCs from the skin of newborn mice (Chang-Rodriguez et al., 2005) , particularly from the declining pool of LCs in Langerinp14 del mice. Therefore, we took advantage of BMDCs obtained from CD11c-p14 del and control mice. Bone marrow precursors cultured in the presence of TGFb1 give rise to a sub-population of Langerin þ LCL-BMDCs (LCLBMDCs) (Valladeau et al., 2002; Becker et al., 2011) . We first aimed to investigate the differentiation of these LCLBMDCs, using this approach as a readout for the TGFb1 sensitivity of p14-deficient BMDCs. It was therefore mandatory to delete p14 at the earliest possible time point during the bone marrow culture-that is, before the cells express Langerin. Therefore, we performed these experiments with CD11c-p14 del mice, rather than with Langerin-p14 del mice. We investigated the effect of p14 deletion on the differentiation of LCL-BMDCs in cultures supplemented with TGFb1 for 8 days. Intriguingly, significantly less LCL-BMDCs could be generated from CD11c-p14 del BM as compared with control cultures, suggesting impaired TGFb1 signaling in p14-deficient BDMCs. Furthermore, CD11c-p14 del LCL-BMDCs exhibited significantly elevated expression of the maturation marker CD86 in terms of both percentage of positive cells and mean fluorescence intensity (Figure 4a and b) . Since a recent report identified bone morphogenetic protein (BMP)7 as an important factor for the differentiation of human LCs (Yasmin et al., 2013) , we tested its effect on the generation of LCL-BMDCs. In contrast to TGFb1, the addition of BMP7 at various concentrations (50-200 ng ml F Sparber et al.
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BMDCs to induce TGFb1-mediated LCL-BMDCs, combined with increased expression of MHC-class II, CD86, and CD40 in cultures supplemented with TGFb1 is reminiscent of the phenotype of Langerin-p14 del LCs in vivo. These findings suggest that p14 deletion affects TGFb1 responsiveness in CD11c þ BMDCs/LCL-BMDCs, as well as LCs.
BMDCs generated from p14-deficient mice reveal decreased expression of TGFbRII and diminished surface binding of TGFb1
Owing to the decreased sensitivity of p14-deficient BMDCs toward TGFb1, we asked whether the surface expression of TGFb1-binding receptors was altered in p14-deficient BMDCs. Indeed, FACS analysis of the TGFbRII subunit revealed a decreased expression level of this receptor on immature CD11c þ CD86 À and mature CD11c þ CD86 þ p14-deficient BMDCs (Figure 5a ). For direct analysis of the binding capacity of TGFb1 to cell surface receptors, we incubated BMDCs on day 8 of culture with biotinylated TGFb1 followed by a fluoresceinated avidin detection reagent. CD11c-p14 del BMDCs bound significantly less TGFb1 as compared with control cells, indicated by the reduced mean fluorescence intensity of TGFb1 staining measured by flow cytometry. This held true for BMDC cultures in the absence and presence of additional TGFb1 (Figure 5b and c) . The reduced TGFb1 binding of BMDCs from TGFb1-containing cultures, as compared with nonsupplemented cultures, was presumably caused by saturation and/or internalization of TGFb receptors. Microscopic analysis further emphasized our flow cytometry data, as p14-deficient BMDCs exhibited reduced fluorescence intensity when incubated with fluorescent TGFb1 (Figure 5d ).
Diminished TGFbRII expression on epidermal LCs from Langerinp14 del mice
For direct assessment of TGFb surface receptor expression on LCs, we used LCs isolated from newborn skin of 21-day-old Langerin-p14 del and control mice. Antibody staining of TGFbRII revealed significantly reduced expression on Langerin-p14 del as compared with control LCs (Figure 6a and b) . In the light of recent publications demonstrating that LC homeostasis is impaired by deficient IL-34 signaling (Greter et al., 2012; Wang et al., 2012) , we analyzed the expression of the IL-34 receptor, i.e., the M-CSF receptor (CD115), on p14-deficient BMDCs and LCs (Supplementary Figure S3 online) . However, we could not detect any differences in the expression of the M-CSF receptor between p14-deficient and control BMDCs/LCs (Supplementary Figure S3 online ). In addition, we did not observe alterations in the expression of the GM-CSFR (CD116), a receptor that has also been implicated in the regulation of LC homeostasis and maturation (Burnham et al., 2000) (Supplementary Figure S3 online) . Thus, p14 deletion negatively regulates the expression of TGFbRII by LCs.
DISCUSSION
Several reports have demonstrated a pivotal role of the late endosomal adaptor molecule p14 in fundamental cellular processes such as cell proliferation, growth factor signaling, and endosomal rearrangement in nonimmune but also immune cells (Teis et al., 2006; Taub et al., 2012) . Analysis of the molecular mechanism underlying these processes revealed a protein complex called LAMTOR, which consists of five molecules: p18 (LAMTOR1), p14 (LAMTOR2), MP1 (LAMTOR3), HPXIP (LAMTOR4), and C7orf59 (LAMTOR5). In our previous work, we demonstrated that CD11c-mediated deficiency of p14 has a profound impact on the population of epidermalresident LCs resulting in a complete loss of LCs in adult mice owing to apoptosis and cell cycle arrest. Moreover, we were able to establish that p14 deletion critically affects signaling of the LAMTOR complex through the ERK MAPK and mTOR cascade in DCs (Sparber et al., 2014) . In this study, we extended our findings in the CD11c-p14 del mice and investigated additional effects of p14 deficiency specifically in LCs. To this end, we deleted p14 under the control of the langerin promoter. Similar to CD11c-p14 del mice, langerin-specific ablation of p14 results in a gradual loss of LCs starting approximately 3 weeks after birth. Importantly, we noticed divergent kinetics for the disappearance of LCs in CD11c-p14 del and Langerin-p14 del mice, with a delayed loss of LCs in the latter. A possible explanation for this discrepancy is the temporally distinctive activation of the cd11c and langerin promoters during neonatal LC development. The expression of CD11c is quickly induced on LCs in the epidermis of newborn mice between days 0 and 4 (Chorro et al., 2009 and Supplementary Figure S1 ). In contrast to CD11c-p14 del mice in which both Langerin-expressing skin DC subsets were reduced (Sparber et al., 2014) , deletion of p14 using Langerin-Cre mice affected only LCs but not Langerin þ dermal DCs. The p14 molecule interferes with many different cellular mechanisms in LCs, e.g., cell cycle arrest and apoptosis, and some of these effects may also affect Langerin þ dermal DCs upon p14 deletion. However, this was not investigated in further detail in this study and remains elusive. Interestingly, in the Langerin-p14 del mice, the population of Langerin þ dermal DCs seems unaltered, which may be caused by the delayed activation of the langerin promoter and the faster turnover and repopulation kinetics of 
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The Endosomal Adaptor p14 Affects TGFb1 Pathway in Langerhans Cells Ginhoux et al., 2007; Poulin et al., 2007) when compared with LCs (Noordegraaf et al., 2010) . In combination, this will lead to a postponed deletion of p14 under the langerin promoter and a fast replacement by new p14-sufficient dermal Langerin þ DCs, which together might conceal the p14-driven loss of this population observed in the skin of CD11c-p14 del mice (Sparber et al., 2014) .
During the past decade, the functional role of LCs has been disputed because of the fact that the three mouse models allowing depletion of Langerin þ dermal DCs and/or LCs (Bennett et al., 2005; Kaplan et al., 2005; Kissenpfennig et al., 2005) yielded conflicting results, particularly in the CHS model for a role of LCs in the efficient induction of CHS, which is in line with several reports suggesting that both LCs and Langerin þ dermal DCs contribute to CHS induction (Bennett et al., 2005 (Bennett et al., , 2007 Bursch et al., 2007; Edelson et al., 2010; Honda et al., 2010; Kel et al., 2010; Noordegraaf et al., 2010; Zahner et al., 2011) . Thus, in the case of Langerin-p14 del mice, the attenuated CHS reaction may be due to the lack of LCs or, alternatively, to functional alterations of Langerin þ dermal DCs. However, we have not further explored the latter possibility in Langerin-p14 del mice in this study.
In our prior work, we established that various signal transduction molecules involved in the mTORC1 pathway are significantly reduced in p14-deficient BMDCs (Sparber et al., 2014) . Here, we take this finding a step further and demonstrate that the differentiation of LCL-BMDCs is compromised upon deletion of p14. To a certain extent, this is reminiscent of previous work, showing that CD11c-specific deletion of the mTORC1-related molecule RAPTOR leads to the loss of LCs in situ (Kellersch and Brocker, 2013) . However, comparison of the LC phenotype of RAPTORdeficient and CD11c-/Langerin-p14 del mice reveals several differences. Most prominently, the enhanced maturation of p14-deficient LCs is not observed in RAPTOR-deficient LCs. As TGFb1 is essential for maintaining the LCs in an immature state in the skin (Kel et al., 2010; Bobr et al., 2012) , we examined the effect of TGFb1 on p14-deleted BMDCs. Moreover, the development of LCs is critically influenced by TGFb1 (Borkowski et al., 1996; Kaplan et al., 2007) , and LC-like cells can be generated in vitro in cultures supplemented with TGFb1 (Strobl et al., 1997; Yamaguchi et al., 1997; Geissmann et al., 1998; Caux et al., 1999) . Indeed, we observed an impaired differentiation of LCLBMDCs from bone marrow of CD11c-p14 del mice in vitro. This was accompanied by higher expression of MHC-class II, CD86, and CD40 indicative of enhanced maturation of CD11c-p14 del as compared with control BMDCs even in the presence of exogenous TGFb1. This finding suggests that p14 expression is essential for the responsiveness of BMDCs toward TGFb1 that would keep these cells in an immature state. In fact, the increased maturation in p14-deleted BMDC mirrors the LC phenotype observed in Langerin-p14 del mice in situ, as well as in mice with a LC-specific deletion of the TGFb receptor 1 (ALK5) (Kel et al., 2010) .
Previous work already demonstrated that deletion of p14 led to an impaired endosomal sorting of the EGFR (Teis et al., 2006) , and thus it is conceivable that p14 deficiency might also affect other growth factor receptors such as TGFb receptors. In line, we detected a reduced surface binding of TGFb1 to p14-deficient BMDCs and less surface expression of TGFbRII on ex vivo-isolated LCs. However, to date, there is no causal link established between the adaptor molecule p14 and the TGFb pathway. Whether p14 deletion in LCs directly affects TGFb receptors by disrupting receptor shuttling processes, or whether the decrease of TGFb receptors is rather an indirect response to the p14 deletion, remains elusive. Previous publications demonstrated that other receptors such as the IL-34-binding M-CSFR (Greter et al., 2012; Wang et al., 2012) and the GM-CSFR (Burnham et al., 2000) are important for the homeostasis and maturation of LCs in situ. However, FACS analysis did not reveal any differences in M-CSFR and GM-CSFR cell surface expression between p14-deficient and p14-sufficient BMDCs and LCs.
Taken together, ablation of p14 under control of the langerin promoter leads to a gradual but delayed loss of LCs as compared with CD11c-p14 del mice owing to increased apoptosis and cell cycle arrest of LCs in the epidermis (Sparber et al., 2014) . The hyporesponsiveness to TGFb1 as observed in CD11c-/Langerin-p14 del mice might enable enhanced apoptosis, as TGFb1 and apoptosis have been linked; e.g., TGFb1 can inhibit apoptosis through the MAPK pathway (Park et al., 2005 , Ohtani et al., 2009 . The enhanced maturation of LCs can be ascribed to the insensitivity of p14-deficient cells to TGFb1 present in the skin, most probably caused by reduced TGFb receptor expression on the surface of LCs. Thus, the discovery that p14 deletion affects the TGFb1 pathway, besides the already known defects in ERK and mTOR signaling, adds an important aspect to the molecular mechanisms that control LC homeostasis in vivo. Hence, the published study on CD11c-/Langerin-p14 del mice (Sparber et al., 2014) and the data presented here are complementary and the finding that the TGFb1 pathway is disturbed in the p14-deficient cells represents an additional explanation as to how the maintenance of immature LCs, as well as their differentiation, are affected in these mice.
MATERIALS AND METHODS

Mice
The following mice were used: Langerin-Cre (Zahner et al., 2011), CD11c-Cre (Caton et al., 2007) , and p14-flox mice (Teis et al., 2006) . Langerin-Cre or CD11c-Cre mice were crossed to p14-flox mice to generate LC-or DC-specific p14-deficient mice: Langerin-Cre/p14
flox/flox and CD11c-Cre/p14 flox/flox (Langerin-p14 del /CD11c-p14 del ). All mice were used at 6-8 weeks of age for experiments with adult mice or younger, as indicated in newborn skin analyses. Mice were bred at the animal facility of the Department of Dermatology and Venereology. All experimental protocols were approved by the Austrian Federal Ministry of Science and Research and performed according to institutional guidelines.
PCR genotyping
DNA was isolated from the tail of mice using Qiagen TailLysis Buffer (Qiagen, Venlo, The Netherlands). Appropriate primers (Microsynth, Balgach, Switzerland) and analysis of particular genetic loci were used, as described previously (Teis et al., 2006) , in order to identify CD11c-p14 del /Langerin-p14 del mice.
Flow cytometry
All antibody-staining steps were performed for 15 minutes at 4 1C. Nonspecific FcR-mediated antibody staining was blocked by incubation with anti-CD16/32 Ab (2.4G2, prepared in-house from hybridoma supernatant). The following antibodies were used: anti-Langerin-Alexa 488 (929.F3, Dendritics, Lyon, France); anti-MHC-class II-FITC (553632), anti-CD86-PE (553692), anti-CD40-PE (55379), and anti-CD103-PE (557495) (all from BD Biosciences, Vienna, Austria); antiCD11c-PE-Cy5.5 (15-0114-81), anti-MHC-class II-APC (17-5321-81), and anti-M-CSFR-APC (17-1152-82, all from eBioscience, San Diego, CA); APC-coupled Life/Dead Cell stain kit (L10120, Life Technologies, Carlsbad, CA); and unconjugated anti-TGFbRII (sc-400) and anti-GM-CSFR alpha (sc-25472, both from Santa Cruz Biotechnology, Santa Cruz, CA). The secondary antibody Alexa fluor488 goat antirabbit IgG was used to detect anti-TGFbRII and anti-GM-CSFR antibodies (A31628, Life Technologies). TGFb-binding assays were carried out using the TGFb1 Fluorokine Kit (NFTG0, R&D Systems, Minneapolis, MN) according to the manufacturer's guidelines. For Annexin-V staining, the Annexin-V-FITC Apoptosis Detection Kit (BMS500FI/300, from eBioscience) was used. Flow cytometry was performed on a BD Biosciences FACSCalibur or BD Biosciences Canto with data analysis using the FlowJo software (Tree Star, Olten, Switzerland).
LN cell suspensions
Skin-draining LNs (brachial, inguinal, and auricular) were teased apart and digested (25 minutes/37 1C) with 0.12 mg ml -1 of DNAse I (Roche, Mannheim, Germany) and 0.5 mg ml -1 collagenase D (Roche). The resulting cell suspension was used for antibody labeling and subsequent flow cytometric analysis.
Skin cell suspensions
For epidermal cell suspensions, ear and trunk skin were floated on 0.8% trypsin (Merck, Darmstadt, Germany) for 15-45 minutes at 37 1C, respectively . For digestion of total skin, trunk skin was cut into small pieces and transferred into Hank's medium (w/ o Ca 2 þ Mg 2 þ , Biochrom AG, Berlin, Germany), supplemented with 0.15 mg ml -1 Liberase (Roche) and 0.12 mg ml -1 DNAse I (Roche) for 1 hour at 37 1C.
Epidermal sheets
Epidermis was separated from the dermis using 0.1 M ammoniumthiocyanate (Merck). The epidermis was peeled off and fixed in acetone (Sigma-Aldrich, Vienna, Austria) or 4% paraformaldehyde (SAV-LP, Flintsbach, Germany). LCs in situ were stained with an antibody for MHC-class II (2G9-FITC, BD Biosciences).
CHS assay
Two-month-old Langerin-p14 del and littermate control mice were sensitized (day 0) by applying 100 ml of 1% (high dose) or 0.5% (low dose) TNCB (dissolved in acetone: olive oil vehicle, at a ratio of 4:1) onto the shaved abdominal skin. Five days later, the sensitized mice were challenged by applying 25 ml of either 0.5% (high dose) or 0.25% (low dose) TNCB onto the dorsal side of the right ear. As a control, the left ear of the mice was treated with the vehicle only. After 24 hours, the ear thickness was measured. The actual ear swelling was calculated by subtracting ear thickness of the vehicletreated ear from the TNCB-treated ear.
BMDCs/TGFb1 blocking assay
Bone marrow was isolated from the hind limbs (femur and tibia). Erythrocytes were removed using an ammonium chloride buffer. Unfractionated bone marrow cells were cultured in complete medium (RPMI-1640 supplemented with 10% fetal calf serum, 2 mM Lglutamine, and 50 mg ml -1 gentamycin (all from PAA, GE Healthcare, Vienna, Austria) containing 20 ng ml -1 of GM-CSF (14-8332-62, eBioscience) for 8 days. LCL-BMDCs were obtained by culturing unfractionated bone marrow in complete medium supplemented with 20 ng ml -1 GM-CSF and 5 ng ml -1 human TGFb1 (100-21C, PeproTech, Hamburg, Germany) for 8 days (Valladeau et al., 2002) .
Statistics
Data were analyzed with unpaired Student's T-test or one-or two2-way analysis of variance with post-hoc test (Bonferroni or Tukey's test). P-values o0.05 were considered significant (*), values o0.01 were considered very significant (**), and values o0.001 were considered highly significant (***). Statistics were performed using PRISM 5.0 (Graphpad Software, La Jolla, CA).
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